Shares of Agilent Technologies A fell 0.6% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 41.03% year over year to $1.10, which beat the estimate of $0.99.
Revenue of $1,586,000,000 rose by 25.77% year over year, which beat the estimate of $1,540,000,000.
Guidance
Q4 EPS expected between $1.15 and $1.18.
Q4 revenue expected to be between $1,630,000,000 and $1,660,000,000.
Conference Call Details
Date: Aug 17, 2021
Time: 04:30 PM
Recent Stock Performance
Company's 52-week high was at $162.52
52-week low: $94.53
Price action over last quarter: Up 20.86%
Company Overview
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2020 sales), cross lab (36% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Just over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (33%) and China (20%) representing the largest country concentrations.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.